Curriculum Vitae-Zhengqiang Yuan

Summary

PhD/Professor

School of Biomedical and Pharmaceutical Sciences

Guangdong University of Technology

Male, DOB:Oct. 1970

Nationality: P.R. China

Dr Yuan graduated from Beijing Agricultural University, China, majoring in microbiology in 1994, and obtained his PhD degree in Molecular Genetics in the Institute of Microbiology, Chinese Academy of Sciences in 2000.

During 2001-2017, He went to UK and worked in the University College London (UCL), University of Glasgow and the Beatson Institute for Cancer Research,Scotland as a research associate or postdoctoral scientist, respectively. During this period, he had been researching in the fields of tumor/cancer,stem cell and biological nanoparticles.

In September 2017, Dr Yuan was recruited by the Guangdong University of Technology as one of the Talented Top 100 Professors and have been directing the Stem Cell and Biological Nanoparticle group for regenerative medicine and diagnostics & treatment of cancers.

In 2016, the mesenchymal stem cell (MSC) therapy that was developed by Dr Yuan successfully entered the phase 2a clinical trial for treatment of lung cancer patients. So far he has had more than 30 research papers published in international or national top journals like JEV, Cancers and the Journal of Virology. Additionally he has had 2 invention patents approved and three patent applications submitted. One of his patents was transferred to the Novartis in Switzerland for 125,000 Swiss francs in 2000.

Enthusiastic and self-inspiring postdoctoral researchers, postgraduate students and undergraduates are working together like a harmonious family in Dr Yuan’s group. They are having extensive collaboration for research and education with other universities, hospitals and industrial enterprises at home or abroad, focusing on basic research as well as development and application.

Education

(1) 09-1997 to 08-2000,Institute of Microbiology, Chinese Academy of Sciences (CAS), PhD student, Supervisor:Professor Tian YC.

(2) 09-1994 to 07-1997, Institute of Microbiology, CAS, Master of Science student, Supervisor:Professor Song DK

(3) 09-1990 to 07-1994, College of Biology, Beijing Agricultural University, Bachelor of Science student, Supervisor: Professor Li Y.

Working Experiences

(1) 2017-09 to today, Professor/PI, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, China

(2) 2011-02 to 2017-08, Research Associate,Division of Medicine, University College London, UK

(3) 04-2005 to 01-2011, Postdoctoral Reseach Fellow,Division of Pathology, University of Glasgow, Supervisor: Professor Nasir L.

(4) 05-2002 to 03-2005, Research Scientist, Beatson Institute for Cancer Research, Scotland, UK

(5) 07-2001 to 04-2002,Reserch Associate, Division of Haematology, Queen’s University of Belfast

(6) 07-1994 to 06-2001,Postgraduate Research Assistant,Institute of Microbiology, CAS, Supervisors: Professors Song DK,Tian YC.

Teaching：three subjects for postgraduate students.

1) Stem Cell and Regenerative Medicine

2) Modern Biopharmaceutical technology

3) Modern Chinese Traditional Medicine  

Top 5 Papers（* Correspondence Author)

1) Changhong Ke, Huan Hou, Jiayu Li, Kui Su, Chaohong Huang , Yue Lin, Zhiqiang Lu, Zhiyun Du, Wen Tan and Zhengqiang Yuan*. Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib. Cancers, 2020. May 4;12(5):1157.（IF 6.126）

2) ZhengQiang Yuan；Kolluri KK；Gowers KHC and Janes SM*; TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy, J Extracellular Vesicles, 2017, 6(1): 1265291. （IF 14.976）

3) ZhengQiang Yuan; Lourenco Sda S; Sage EK; Kolluri KK; Lowdell MW; Janes SM*;  Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy, Cytotherapy, 2016,18(7):860-869. (IF 4.218）

4) ZhengQiang Yuan; Kolluri KK; Sage EK; Gowers KH; Janes SM*; Mesenchymal stromal cell delivery of full-length TNF-related apoptosis-inducing ligand is superior to soluble type for cancer therapy, Cytotherapy, 2015,17(7):885-896. （IF 4.218）

5) Yuan ZQ, Nicolson L, Marchetti B, Gault EA, Campo MS, Nasir L*. Transcriptional changes induced by bovine papillomavirus type 1 in equine fibroblasts. J Virol. 2008 Jul;82(13):6481-91. doi: 10.1128/JVI.00429-08. （IF 5.33）